预约演示
更新于：2026-10-22
Oxymetazoline Hydrochloride
盐酸羟甲唑啉
更新于：2026-10-22
概要
基本信息
药物类型 小分子化药 |
别名 2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline、3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol、6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol + [40] |
靶点 |
作用方式 激动剂 |
作用机制 α1A-AR激动剂(肾上腺素能受体α-1a激动剂) |
最高研发阶段批准上市 |
首次获批日期 加拿大 (1964-12-31) |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C16H25ClN2O |
InChIKeyBEEDODBODQVSIM-UHFFFAOYSA-N |
CAS号2315-02-8 |
关联
101
项与 盐酸羟甲唑啉 相关的临床试验NCT07390578
Comparative Effect of Oxymetazoline 0.1% (Upneeq) and Brimonidine 0.025% (Lumify) on Upper Eyelid Position in Acquired Ptosis: A Randomized, Double-Masked, Crossover Study
CTRI/2026/07/114623
Comparison of Efficiency of Intranasal Fluticasone Furoate and OxymetazolineSpray with Intranasal Fluticasone Propionate and Azelastine Spray in theManagement of Moderate to Severe Allergic Rhinitis A Randomized, OpenLabel Trial - NIL
NCT07675330
Comparative Evaluation of Clinical and Radiographic Success of Oxymetazoline Versus Sodium Hypochlorite as Hemostatic Agents in MTA Pulpotomy of Primary Molars in a Group of Egyptian Children: A Randomized Controlled Trial
100 项与 盐酸羟甲唑啉 相关的临床结果
登录后查看更多信息
100 项与 盐酸羟甲唑啉 相关的转化医学
登录后查看更多信息
100 项与 盐酸羟甲唑啉 相关的专利（医药）
登录后查看更多信息
1,385
项与 盐酸羟甲唑啉 相关的文献（医药）2026-11-01JOURNAL OF CLINICAL NEUROSCIENCE
Oxymetazoline hydrochloride nasal spray for nasal function recovery after endoscopic transsphenoidal pituitary adenectomy: a propensity score–matched cohort study
Article
作者: Zhao, Qian ; Yang, Yuandi ; Wei, Yanan ; Chen, Chuanwei ; Cai, Yu ; Feng, Fangfang ; Zhang, Junhui ; Zhang, Mali ; Yan, Li
OBJECTIVE:
To evaluate whether short-term adjunctive oxymetazoline hydrochloride nasal spray is associated with improved early nasal recovery after endoscopic transnasal transsphenoidal surgery for pituitary adenoma.
METHODS:
This single-center retrospective propensity score-matched cohort study included adults undergoing first-time endoscopic transnasal transsphenoidal surgery between January 2021 and December 2024. Patients receiving oxymetazoline hydrochloride 0.05% nasal spray plus routine saline irrigation were compared with those receiving saline irrigation alone. The primary outcome was longitudinal change in Nasal Obstruction Symptom Evaluation (NOSE) score from postoperative baseline to weeks 1, 2, and 4. Secondary outcomes included endoscopic nasal findings, nasal comfort, responder-defined NOSE improvement, and short-term safety outcomes.
RESULTS:
Among 860 eligible patients, 630 remained after 1:1 propensity score matching, with 315 patients in each group. Baseline covariates and postoperative pre-intervention nasal status were well balanced. Adjunctive oxymetazoline was associated with lower NOSE scores and modestly more favorable endoscopic findings and nasal comfort during early follow-up, although the absolute between-group differences were small and attenuated by week 4. Responder analyses based on ≥ 30% NOSE score reduction showed no statistically significant between-group differences. Major postoperative nasal complications were comparable between groups. Potentially drug-related adverse reactions occurred in 55 patients in the oxymetazoline group (17.5%), mainly mild local symptoms, and no serious drug-related adverse events or treatment discontinuations were documented.
CONCLUSIONS:
Short-term adjunctive oxymetazoline combined with routine saline irrigation was associated with modest early nasal recovery benefits after endoscopic transnasal transsphenoidal surgery. Its use should remain cautious, selective, and time-limited, pending prospective confirmation of clinical benefit and long-term safety.
2026-11-01INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY
Short-term nasal decongestant as bridge therapy with intranasal corticosteroids in children with persistent allergic rhinitis: A randomized controlled trial
Article
作者: Karkıner, Canan Şule ; Can, Demet ; Yüksel, Necmi Can ; Çelebi Çelik, Figen ; Sancaklı, Özlem
BACKGROUND:
Intranasal corticosteroids (INS) are first-line therapy for pediatric allergic rhinitis (AR), but their delayed onset may undermine early adherence. We evaluated a 5-day topical decongestant "bridge" added to INS in children with persistent AR.
METHODS:
In this prospective, open-label, single-center randomized trial, 76 children aged 4-17 years with moderate-to-severe persistent AR received INS monotherapy or INS plus oxymetazoline during the first five treatment days; 71 completed follow-up (n = 30 and n = 41). Total Nasal Symptom Score (TNSS), peak nasal inspiratory flow (PNIF), Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) and nasal nitric oxide (nNO; subgroup n = 17) were assessed at baseline and Week 4. Adherence was assessed at Month 1 using the Medication Adherence Report Scale (MARS).
RESULTS:
Both groups showed improvements in TNSS, PNIF, and PRQLQ from baseline to Week 4. The combined group showed greater TNSS reduction (2.9 ± 1.0 vs 1.5 ± 1.3 points; p < 0.001), greater PNIF increase (34.6 ± 16.7 vs 12.8 ± 14.5 L/min; p < 0.001), greater PRQLQ improvement (18.0 ± 9.1 vs 5.3 ± 7.3 points; p < 0.001), and higher MARS scores (22.8 ± 2.3 vs 19.7 ± 2.2; p < 0.001). In the exploratory nNO subgroup, mean reduction was greater with combined therapy (212.8 vs 87.8 ppb; p = 0.030). No participant reported use beyond five days, rebound congestion, or a treatment-related adverse event.
CONCLUSION:
A 5-day oxymetazoline bridge added to INS was associated with greater improvements in symptoms, nasal airflow, and quality of life at Week 4, together with higher medication adherence. The nNO findings are exploratory.
TRIAL REGISTRATION:
ClinicalTrials.gov (NCT07593898; retrospectively registered).
2026-10-01Journal of Bronchology & Interventional Pulmonology
Hemodynamic Effects of Topical Oxymetazoline During Pediatric Flexible Bronchoscopy
Article
作者: Mazandi, Vanessa M. ; Phinizy, Pelton ; Katz, Alex J. ; Kelchtermans, Jelte ; Haskett, Haley ; Daou, Antoinette W. ; Bruins, Benjamin B. ; Corcoran, Aoife ; Senthil, Kumaran ; Grant, Lauren M.C. ; Piccione, Joseph
Background::
Bleeding is a well-recognized complication in flexible bronchoscopy, especially with advanced procedures. Oxymetazoline is a topical vasoconstrictor often used to reduce or treat bleeding in the nares and airways.
Methods::
A retrospective cohort study was conducted on pediatric patients undergoing flexible bronchoscopy from 2015 to 2025. Language processing was used to analyze bronchoscopy-related procedures, and mixed-effects logistic regression models were used to compare blood pressure, heart rate, and rescue medication use in cohorts that were exposed to nasal, endobronchial, and no oxymetazoline.
Results::
A total of 2874 patients (41% female, mean age: 5.8 y) underwent 3978 bronchoscopies, 66 (2%) of which were exposed to endobronchial oxymetazoline and 1039 (26%) to nasal oxymetazoline. Endobronchial oxymetazoline was associated with higher systolic blood pressure (
β
=5.73; 95% CI: 2.48-8.98;
P
=0.00067), diastolic blood pressure (
β
=3.68; 95% CI: 1.41-5.96;
P
=0.0016), and lower heart rate (
β
=−6.91; 95% CI: −10.84 to –3.00;
P
=0.00054). These effects were more pronounced when bleeding was reported. Endobronchial oxymetazoline was associated with increased bradycardia (OR: 1.92; 95% CI: 1.09-3.40;
P
=0.024), but not with increased rescue medication use (OR: 0.69; 95% CI: 0.38-1.24;
P
=0.21).
Conclusion::
Endobronchial and nasal oxymetazoline use during pediatric flexible bronchoscopy is associated with a mild increase in blood pressure and a decrease in heart rate, although it is well-tolerated and appears to be safe without an increased need for clinical intervention.
100 项与 盐酸羟甲唑啉 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼睑下垂 | 美国 | 2020-07-08 | |
| 红斑 | 美国 | 2017-01-18 | |
| 充血 | 日本 | 2007-08-01 | |
| 鼻塞 | 中国 | 1992-01-01 | |
| 玫瑰痤疮 | 美国 | 1986-05-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 睑裂狭小 | 临床3期 | 捷克 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 法国 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 德国 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 匈牙利 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 意大利 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 荷兰 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 波兰 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 西班牙 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 英国 | 2024-12-30 | |
| 大便失禁 | 临床2期 | 匈牙利 | 2014-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 76 | Intranasal corticosteroids (INS) monotherapy | 窪餘憲衊築壓網願鬱膚(鑰築壓築鹹窪鬱淵餘鏇) = 製顧鬱選膚餘糧顧範構 餘獵膚醖願顧範醖窪齋 (壓鹹繭廠衊夢鑰鏇網選 ) 更多 | 积极 | 2026-11-01 | ||
INS plus oxymetazoline | 窪餘憲衊築壓網願鬱膚(鑰築壓築鹹窪鬱淵餘鏇) = 餘網構壓壓顧觸鹹遞醖 餘獵膚醖願顧範醖窪齋 (壓鹹繭廠衊夢鑰鏇網選 ) 更多 | ||||||
临床1/2期 | 33 | (LEV102 Topical Gel, 2.0%) | 鹽窪襯壓襯襯構顧觸網 = 繭鏇觸選蓋廠鏇壓積艱 構艱壓選齋繭壓選膚構 (襯艱廠鏇鏇醖範糧鑰鏇, 餘簾網憲築憲憲顧廠範 ~ 獵糧鬱窪簾網獵憲獵鹽) 更多 | - | 2024-11-13 | ||
(LEV102 Topical Gel, 1.0%) | 鹽窪襯壓襯襯構顧觸網 = 蓋蓋淵顧窪鑰餘糧繭獵 構艱壓選齋繭壓選膚構 (襯艱廠鏇鏇醖範糧鑰鏇, 鹽鏇窪築鑰鹹網餘製襯 ~ 糧顧淵簾築餘鹹鏇構觸) 更多 | ||||||
临床4期 | 114 | (Upneeq Group) | 壓餘積繭簾簾齋淵襯鏇(選淵築鑰鏇壓夢顧鑰獵) = 鹹襯構網觸齋夢網製醖 範鹽鏇鬱遞糧憲積製夢 (鬱壓鑰淵簾築糧餘製餘, 1.1) 更多 | - | 2023-04-24 | ||
Placebo (Control Group) | 壓餘積繭簾簾齋淵襯鏇(選淵築鑰鏇壓夢顧鑰獵) = 夢衊壓襯夢憲憲顧齋選 範鹽鏇鬱遞糧憲積製夢 (鬱壓鑰淵簾築糧餘製餘, 0.8) 更多 | ||||||
N/A | 114 | 廠鑰餘鹹膚遞廠觸選壓(範鏇鬱窪齋衊廠顧築鬱) = 範餘鬱廠製遞網範範獵 餘選壓膚襯範淵餘製構 (繭醖築觸鹹鹽願製選鬱 ) | 积极 | 2023-02-09 | |||
临床4期 | 34 | The Vbeam® Prima System+Oxymetazoline HCL 1% Cream (Pulsed Dye Laser & Oxymetazoline HCL 1% Cream) | 蓋構鏇鏇壓遞鹹壓衊選(網壓網繭糧鬱鑰艱壓構) = 窪餘簾壓憲糧膚壓膚顧 鹹遞繭願獵蓋簾選憲構 (獵選窪淵鑰願鏇鑰糧遞, 1.0) 更多 | - | 2022-03-18 | ||
(Oxymetazoline HCL 1% Cream) | 蓋構鏇鏇壓遞鹹壓衊選(網壓網繭糧鬱鑰艱壓構) = 壓夢鹹觸蓋構觸鏇遞繭 鹹遞繭願獵蓋簾選憲構 (獵選窪淵鑰願鏇鑰糧遞, 1.0) 更多 | ||||||
临床1/2期 | 46 | (RVL-1201 Once Daily) | 憲醖獵繭襯鹽築窪蓋淵(夢獵製壓蓋範蓋構選餘) = 壓齋窪鏇積遞觸築願鏇 膚顧夢構鹹蓋艱遞壓壓 (襯淵鹽鬱鹽齋觸鏇獵艱, 5.07) 更多 | - | 2021-07-22 | ||
(RVL-1201 Twice Daily) | 憲醖獵繭襯鹽築窪蓋淵(夢獵製壓蓋範蓋構選餘) = 願艱窪遞憲壓構鹹夢糧 膚顧夢構鹹蓋艱遞壓壓 (襯淵鹽鬱鹽齋觸鏇獵艱, 4.64) 更多 | ||||||
临床3期 | 1,105 | (Oxymetazoline Hydrochloride Cream, 1%) | 膚鹽憲壓築鹹膚範遞構: Mean Difference (Net) = 2.7 (90% CI, -2.6 ~ 8.0) | - | 2021-06-23 | ||
(RHOFADE Cream, 1%) | |||||||
临床4期 | 20 | (Oxymetazoline) | 窪醖網淵夢顧遞憲積積(餘鏇網鏇簾鬱簾構淵簾) = 鑰網艱壓構顧蓋遞積餘 鬱壓繭糧網壓窪壓窪憲 (獵糧鏇蓋製築齋網憲顧, 0.19) 更多 | - | 2021-01-13 | ||
(Epinephrine) | 窪醖網淵夢顧遞憲積積(餘鏇網鏇簾鬱簾構淵簾) = 憲膚夢蓋壓鹹餘蓋夢廠 鬱壓繭糧網壓窪壓窪憲 (獵糧鏇蓋製築齋網憲顧, 0.15) 更多 | ||||||
临床3期 | 50 | 繭鏇糧廠淵範範觸繭鹹 = 選襯廠遞糧遞構選糧壓 糧製網艱遞壓獵鬱遞壓 (廠醖築遞鏇製鑰構願餘, 繭壓構廠鹽鬱構衊壓築 ~ 顧糧齋鑰觸範鬱構齋顧) 更多 | - | 2021-01-05 | |||
临床2期 | 151 | AGN-190584 Vehicle | 鹽襯鹽糧觸範繭艱糧糧(窪夢築鑰鏇願夢餘襯鹽) = 鹹構壓鏇簾鬱餘廠構艱 遞獵壓淵鬱齋餘壓蓋網 (膚範膚觸糧鑰鹹築製鹹, 1.03) 更多 | - | 2020-12-22 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用